Physician profile
Ralph A Jackson
NPI 1558467043
$2,931.29
in general payments reported to CMS, 2019-2025
27 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $727 · 2021: $261 · 2022: $130 · 2023: $281 · 2024: $245 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $417.43 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $359.43 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $359.41 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.01 | 2019-2024 | Tradjenta, Synjardy |
| Lilly USA, LLC | $283.37 | 2019-2025 | Mounjaro, Kisunla |
| Janssen Pharmaceuticals, INC | $178.53 | 2019-2021 | |
| Pfizer INC. | $169.81 | 2019-2024 | |
| Amgen INC. | $117.18 | 2019-2025 | Krystexxa |
| Astellas Pharma US INC | $92.75 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.88 | 2019-2023 | Xifaxan, Trulance |
| Abbvie INC. | $75.65 | 2021-2022 | |
| Amarin Pharma, INC. | $68.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.41 | 2019 | |
| Allergan, INC. | $49.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.20 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.20 | 2022-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $32.78 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $30.67 | 2025 | |
| Exact Sciences Corporation | $21.59 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $20.53 | 2020 | |
| Medtronic USA, INC. | $20.10 | 2019 | |
| Abbott Laboratories | $19.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2023 | |
| Sanofi Pasteur INC. | $18.07 | 2020 | |
| Esperion Therapeutics, INC. | $17.05 | 2020 | |
| Hikma Pharmaceuticals USA | $14.81 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.33 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.